Publication

Number of items: 10.
27 July 2026
  • Possible signals of ocular disorders associated with gabapentinoids: A three-arm study. (2026) Mya Murray, Amira Guirguis, Paul Deslandes, John Martin Corkery, Stefania Chiappini, Mariacristina Parravano and Fabrizio Schifano picture_as_pdf
    • 30 October 2024
  • Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. (2024) Chiara Montemitro, Alessio Mosca, Stefania Chiappini, Andrea Miuli, Fabrizio Schifano, Maria Josè Gordillo Montano, Cristina Merino Del Villar, Rita Allegretti, Carlotta Marrangone, Gilberto Di Petta, Domenico De Berardis, Mauro Pettorruso and Giovanni Martinotti
    • 31 March 2024
  • 3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18 F-FDG PET/CT Case Report. (2024) Maria Pepe, Marco Di Nicola, Fabrizio Cocciolillo, Stefania Chiappini, Giovanni Martinotti, Maria Lucia Calcagni and Gabriele Sani
    • 6 March 2024
  • Shorter and Longer Antibiotic Durations for Respiratory Infections: To Fight Antimicrobial Resistance—A Retrospective Cross-Sectional Study in a Secondary Care Setting in the UK. (2024) Rasha Abdelsalam Elshenawy, Nkiruka Umaru and Zoe Aslanpour
    • 18 August 2023
  • An update on psychoactive substances: Pharmacology and Toxicology issues. (2023) Stefania Chiappini and Fabrizio Schifano description
    • 11 July 2023
  • Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. (2023) Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano
    • 31 December 2022
  • Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? (2022) Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini and Giuseppina Cantarella
    • 27 May 2022
  • Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John M. Corkery, Giovanni Martinotti, Daniel R. Harris and Fabrizio Schifano
    • 1 May 2022
  • A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John Martin Corkery, Giovanni Martinotti and Fabrizio Schifano
    • 26 July 2021
  • The psychonauts’ benzodiazepines; quantitative structure-activity relationship (QSAR) analysis and docking prediction of their biological activity. (2021) Valeria Catalani, Michelle Botha, John Martin Corkery, Amira Guirguis, Alessandro Vento, Norbert Scherbaum and Fabrizio Schifano description
    • This list was generated on Tue Sep 22 03:00:30 2026 BST.